Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Serology test
View:
Post by sparky6 on Nov 09, 2020 9:13am

Serology test

Looks again like our leadership in this company at the board and executive level is a day late and a dollar short.
Comment by Gbathat on Nov 09, 2020 9:22am
I think assessment of vaccine protection duration is one of their target markets.  Did Pfizer indicate the length of vaccine effectiveness?  Does it vary by individual?  How could we measure that on a large scale?
Comment by retiredcop on Nov 09, 2020 9:46am
Thats exactly what alot of different people were asking the CEO today... how long does the vaccine last and the answer was pretty clear... he does not know .. the other question was what does the effectiveness actually mean... did they find that  the people who took the 2 doses didnt get the virus,?  or were the virus effects not as severe or that they recovered quicker then the placebo ...more  
Comment by Actuarial on Nov 09, 2020 11:14am
No one truely care about serology test. As long as we have vaccine, the game is over. Vaccine = lock down. Covid-19 would disppear soon alike SARS. PMN is too late to be in the game, again and again. Don't depend on it. If there is no clinical trial on PMN310, there is no chance SP moving up. It is sadly true.
Comment by retiredcop on Nov 09, 2020 11:35am
Covid is going to disappear soon .What rabbit hole do you live in?  We are just starting to see the real impact of this virus is... the vaccines production is in a frenzy... as much as we want to ... but you cant shorten the time it takes to know if the vaccine is effective.over an extended period of time.. the covid serology test is one of the better ways of answering a number of questions ...more  
Comment by Alex1726 on Nov 09, 2020 2:08pm
Covid is going to disappear soon .What rabbit hole do you live in?   I don' t know where his rabbit hole is but i know that yours is not too far away from his.
Comment by retiredcop on Nov 09, 2020 2:24pm
WHAT THE HECK IS GOING ON!  Alex its not Friday, what are you doing here ?   
Comment by Alex1726 on Nov 09, 2020 2:36pm
I got covid and i have to stay home, why don"t you do as i asked you friday something to help like sending an e-mail to your idol asking him something that could be helpful for shareholders. We already have Goldstein and William repeating always the same bu...sh..it , we don' t need you to do the same. Come on RC do something usefull for once.
Comment by M101 on Nov 09, 2020 12:04pm
But it did get us to network in Canada, despite Elliot.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities